Safety and Effectiveness of a Multifocal Intraocular Lens (IOL)
Cataract
About this trial
This is an interventional treatment trial for Cataract focused on measuring cataract, tecnis, multifocal, intraocular lens
Eligibility Criteria
Inclusion Criteria:
- Visual potential of 20/30 or better in each study eye
- Preoperative BCDVA worse than Snellen 20/40 or worse than 20/30 in the presence of glare (as measured using a Snellen chart with BAT at medium)
- Naturally dilated pupil size (in dim light) > 4.0 mm (with no dilation medications) for each study eye
- Preoperative corneal astigmatism of 1.0 D or less
Exclusion Criteria:
- Use of systemic or ocular medications that may affect vision (the use of any miotic agent is specifically contraindicated)
- Acute or chronic disease or illness that would increase the operative risk or confound the study outcome(s),(e.g., diabetes mellitus, immunocompromised, connective tissue disease, etc.)
- Uncontrolled systemic or ocular disease
- History of ocular trauma or prior ocular surgery or subjects expected to require retinal laser treatment or other surgical intervention
Presence of ocular pathology other than cataract such as:
- Amblyopia or strabismus
- Corneal abnormalities
- Pupil abnormalities
- Capsule or zonule abnormalities
- Intraocular inflammation
- Known pathology that may affect visual acuity and/or are predicted to cause future acuity losses to a level of 20/30 or worse (e.g. macular degeneration)
- Requiring an intraocular lens outside the study diopter range
- Contact lens usage prior to study procedure (time interval dependent upon contact lens type)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Tecnis Multifocal IOL group
CeeOn 911A monofocal control IOL group
Subjects implanted bilaterally with the Tecnis Multifocal IOL. Participants were enrolled in this arm in the original study and also in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
Subjects implanted bilaterally with the CeeOn 911A monofocal IOL. Participants enrolled in this arm only in the original study; no control subjects were enrolled in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.